DDInter1631 DDInter1427
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed.
Pentoxyverine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nalbuphine
Pentoxyverine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexanolone
Pentoxyverine {u} may lead to a major life threatening interaction when taken with {v} Rasagiline
Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Pentoxyverine may lead to a major life threatening interaction when taken with Rasagiline